ArticleNature methods2008
Linking SNPs to CAG repeat length in Huntington's disease patients.
Article in Nature methods, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 39 citations in OpenAlex.
- CRISPR-based gene therapy for huntington's disease: current advances and future prospects.Neurogenetics · 2025Review
- Generating a Cell Model to Study ER Stress in iPSC-Derived Medium Spiny Neurons from a Patient with Huntington's Disease.International journal of molecular sciences · 2025Article
- Therapeutic Strategies in Huntington's Disease: From Genetic Defect to Gene Therapy.Biomedicines · 2022Review
- Investigational Assay for Haplotype Phasing of the Huntingtin Gene.Molecular therapy. Methods & clinical development · 2020Article
- Therapies targeting DNA and RNA in Huntington's disease.The Lancet. Neurology · 2017Review
- Allele-Selective Suppression of Mutant Huntingtin in Primary Human Blood Cells.Scientific reports · 2017Article
- Protective Effect of Antioxidants on Neuronal Dysfunction and Plasticity in Huntington's Disease.Oxidative medicine and cellular longevity · 2017Review
- Does the Mutant CAG Expansion in Huntingtin mRNA Interfere with Exonucleolytic Cleavage of its First Exon?Journal of Huntington's disease · 2016Article
- Making (anti-) sense out of huntingtin levels in Huntington disease.Molecular neurodegeneration · 2015Article
- Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington's disease.Human gene therapy · 2014Article
- Gene therapy for misfolding protein diseases of the central nervous system.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2013Review
- Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis.Neuron · 2012Article
- Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington's disease.Biochimica et biophysica acta · 2012Review
- Nucleic Acid-Based Therapy Approaches for Huntington's Disease.Neurology research international · 2012Article
- Using non-coding small RNAs to develop therapies for Huntington's disease.Gene therapy · 2011Review
- Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin.Molecular therapy : the journal of the American Society of Gene Therapy · 2011Article
- Tailor-made RNAi knockdown against triplet repeat disease-causing alleles.Proceedings of the National Academy of Sciences of the United States of America · 2010Article
- Huntington's disease: silencing a brutal killer.Experimental neurology · 2009Review
- Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice.Molecular therapy : the journal of the American Society of Gene Therapy · 2009Article
- Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients.Current biology : CB · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Allele-specific silencing using small interfering RNAs targeting heterozygous single-nucleotide polymorphisms (SNPs) is a promising therapy for human trinucleotide repeat diseases such as Huntington's disease. Linking SNP identities to the two HTT alleles, normal and disease-causing, is a prerequisite for allele-specific RNA interference. Here we describe a method, SNP linkage by circularization (SLiC), to identify linkage between CAG repeat length and nucleotide identity of heterozygous SNPs using Huntington's disease patient peripheral blood samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.